North Estonia Medical Centre: Difference between revisions
No edit summary |
(→Trials) |
||
| Line 6: | Line 6: | ||
== [[Trials]] == | == [[Trials]] == | ||
=== [https://clinicaltrials.gov/ct2/show/NCT03104699?cond=Cancer&locn=%22North+Estonia+Medical+Centre%22&cntry=EE&lupd_s=10%2F21%2F2022&lupd_d=14 Study of AGEN2034 in Advanced Tumors and Cervical Cancer] === | |||
'''Summary:''' This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen. | |||
'''Sponsor, manager, or home institution:''' Agenus Inc. | |||
'''Intervention/Treatment:''' Drug: AGEN2034 | |||
'''Number of patients:''' 211 participants | |||
'''Beginning Date:''' April 7, 2017 | |||
'''Last Update:''' November 3, 2022 | |||
'''Recruitment Status:''' Completed. | |||
'''Cancer areas of interest:''' Advanced Cancer and Cervical Cancer | |||
== [[Experts]] == | == [[Experts]] == | ||
Revision as of 17:14, 4 November 2022
The North Estonia Medical Centre is one of the top healthcare providers in the country. The Medical Center’s statutes states their goal is "to provide high-quality, specialized medical care and ambulance services, to be the learning base of training that precedes and follows the acquiring of health care professionals’ qualifications and does healthcare-related study and research work."
Trials
Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Summary: This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Sponsor, manager, or home institution: Agenus Inc.
Intervention/Treatment: Drug: AGEN2034
Number of patients: 211 participants
Beginning Date: April 7, 2017
Last Update: November 3, 2022
Recruitment Status: Completed.
Cancer areas of interest: Advanced Cancer and Cervical Cancer
